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Abstract
Introduction To lower the barrier for initiating insulin
treatment and obtain adequate glycemic control in type 2
diabetes mellitus (T2DM), new basal insulin preparations
with improved pharmacological properties and conse-
quently a lower risk of hypoglycemia are needed. The
objective of this trial was to confirm the efficacy and
compare the safety of insulin degludec (IDeg) with insulin
glargine (IGlar) in a multinational setting with two thirds of
subjects enrolled in China.
Methods This was a 26-week, randomized, open-label,
parallel-group, treat-to-target, non-inferiority trial in 833
subjects with T2DM (48 % were female, mean age
56 years, diabetes duration 8 years), inadequately con-
trolled on oral antidiabetic drugs (OADs). Subjects were
randomized 2:1 to once-daily IDeg (555 subjects) or IGlar
(278 subjects), both with metformin. The primary endpoint
was the change from baseline in glycosylated hemoglobin
(HbA1c) after 26 weeks.
Results The completion rate was high (IDeg 94.2 %;
IGlar 91.4 %). Mean HbA1c decreased from 8.3 to 7.0 % in
both groups. Estimated treatment difference (ETD) [95 %
confidence interval (CI)] IDeg-IGlar in change from
baseline was -0.05 % points [-0.18 to 0.08], confirming
the non-inferiority of IDeg to IGlar. The proportion of
subjects achieving HbA1c \7.0 % was 54.2 and 51.4 %
with IDeg and IGlar, respectively (estimated odds ratio
[95 % CI] IDeg/IGlar: 1.14 [0.84 to 1.54]). The mean
decrease in fasting plasma glucose, self-measured plasma
glucose profiles, and insulin dose were similar between
groups. Numerically lower rates of overall (estimated rate
ratio [95 % CI] IDeg/IGlar: 0.80 [0.59 to 1.10]) and noc-
turnal (0.77 [0.43 to 1.37]) confirmed hypoglycemia were
observed with IDeg compared with IGlar. No treatment
differences in other safety parameters were found. Subjects
were more satisfied with the IDeg device compared with
the IGlar device as reflected by the total Treatment Related
Impact Measures-Diabetes Device score (ETD [95 % CI]
IDeg-IGlar: 2.2 [0.2 to 4.3]).
Conclusion IDeg provided adequate glycemic control
non-inferior to IGlar and a tendency for a lower hypo-
glycemia rate. IDeg is considered suitable for initiating
insulin therapy in T2DM patients on OADs requiring
intensified treatment.
Trial Registration Clinicaltrials.gov NCT01849289.
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Key Points
New basal insulin preparations with improved
pharmacological properties and consequently a
lower risk of hypoglycemia are needed to lower the
barrier for initiating insulin treatment and obtain
adequate glycemic control in type 2 diabetes
mellitus. The objective of this randomized, open-
label, treat-to-target trial was to confirm the efficacy
and compare the safety of insulin degludec (IDeg)
with insulin glargine (IGlar) in a multinational
setting with two thirds of subjects enrolled in China
The non-inferiority of IDeg to IGlar in glycemic
control as measured by changes in glycosylated
hemoglobin was confirmed, and the proportion of
subjects reaching the glycemic targets of
glycosylated hemoglobin\7.0 and B6.5 %, the
decrease in fasting plasma glucose, self-measured
plasma glucose profiles, and insulin doses at the end
of treatment were similar between IDeg and IGlar.
Furthermore, numerically lower rates of overall and
nocturnal confirmed hypoglycemic episodes (by 20
and 23 %, respectively) were observed with IDeg
compared with IGlar, although not statistically
significantly different
Overall, once-daily IDeg provided adequate
glycemic control non-inferior to IGlar and a
tendency for a lower rate of hypoglycemia. IDeg is
considered suitable for initiating insulin therapy in
patients with type 2 diabetes on oral antidiabetic
drugs requiring intensified treatment
1 Introduction
Globally, around 415 million people are living with dia-
betes mellitus, a number that is expected to rise with 227
million over the next 25 years. Approximately 90 % have
type 2 diabetes mellitus (T2DM), and the number of people
with T2DM is currently increasing in every country [1].
Specifically, in China, the prevalence of diabetes has
increased from less than 1 % in 1980 to 11.6 % in 2010,
making China the country with the highest absolute disease
burden of diabetes in the world [1, 2].
Accumulating evidence supports early initiation of
insulin treatment in T2DM. The UK Prospective Diabetes
Study (UKPDS) demonstrated that intensive glycemic
control in newly diagnosed patients with T2DM reduced
long-term micro- and macrovascular complications [3].
Tight glycemic control early after diagnosis of T2DM may
lead to slower progression of the disease and delay the need
for intensified treatment [4]. Insulin is recommended as the
most powerful option of second-line therapy in T2DM if
individualized glycemic targets are not met within a rea-
sonable time frame [5]. An important focus of insulin
initiation in T2DM is that glycemic control should be
achieved while still ensuring a low risk of hypoglycemia
because the risk of hypoglycemia is a major reason for
clinical inertia in initiating insulin treatment in T2DM [6].
Unfortunately, most current basal insulin analogs do not
allow glycemic control over a full 24-h period, and are
often limited by their day-to-day variability and thereby a
potentially higher risk of hypoglycemia [7]. Therefore,
basal insulin preparations with improved pharmacological
properties and an even lower risk of hypoglycemia are
needed.
Insulin degludec (IDeg) is an insulin analog with an
ultra-long duration of action [42 h. Owing to a unique
protraction mechanism with IDeg monomers being slowly
and continuously released into the circulation, a
stable glucose-lowering effect across 24 h and less day-to-
day variability in the glucose-lowering effect has been
observed with IDeg compared with insulin glargine (IGlar).
With these pharmacological properties, IDeg allows for
flexibility in dosing without compromising glycemic con-
trol or increasing the risk of hypoglycemia [7]. Clinical
studies have confirmed that IDeg is non-inferior to IGlar in
HbA1c reduction with once-daily dosing in insulin-naı¨ve or
insulin-treated patients with T2DM and causes a reduction
in fasting plasma glucose (FPG) greater than or similar to
that of IGlar [8–11]. Furthermore, meta-analyses have
shown that in insulin-naı¨ve patients with T2DM the total
daily dose at end of trial was 10 % lower with IDeg than
with IGlar [12], and that IDeg compared with IGlar
reduced the rate of overall and nocturnal confirmed hypo-
glycemic episodes in patients with T2DM [13]. In addition,
using the Treatment Related Impact Measures-Diabetes
Device (TRIM-D Device) questionnaire [14], the IDeg
delivery device has been rated significantly better for
device function and with less device bother [15] compared
with the IGlar delivery device.
The rationale for the current trial was to confirm the
efficacy of IDeg and to compare the safety of IDeg with
IGlar, both in combination with metformin in insulin-naı¨ve
patients with T2DM in a multinational trial, with two thirds
of the patients enrolled in China to support IDeg registra-
tion in China.
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2 Methods
2.1 Trial Design
This was a 26-week, randomized, open-label, parallel-
group, treat-to-target trial conducted at 68 centers in Brazil,
Canada, China, South Africa, Ukraine, and United States
between June 2013 and May 2014. All procedures followed
were in accordance with the ethical standards of the
responsible committee on human experimentation (insti-
tutional and national) and with the Helsinki Declaration of
1964, as revised in 2000 and 2008 [16], and Good Clinical
Practice [17]. Informed consent was obtained from all
subjects for being included in the trial. The trial was reg-
istered on ClinicalTrials.gov (#NCT01849289).
2.2 Subjects
The trial included insulin-naı¨ve subjects with T2DM, who
were inadequately controlled on oral antidiabetic drugs
(OADs) and qualified for intensified treatment. Individuals
were eligible to participate if they were C18 years of age,
had T2DM diagnosed clinically for C6 months, had HbA1c
between 7.0 and 10.0 % (both inclusive), body mass index
B40 kg/m2, were insulin naı¨ve, and treated with
stable doses of OADs (metformin monotherapy or in
combination with an insulin secretagogue [sulfonylurea or
glinide], dipeptidyl peptidase IV inhibitor, or a-glucosi-
dase-inhibitors [acarbose]) for C3 months prior to ran-
domization. Exclusion criteria included treatment with
thiazolidinedione or glucagon-like peptide-1 receptor
agonists within the previous 3 months prior to screening,
cardiovascular disease within 6 months prior to screening,
uncontrolled severe hypertension, impaired hepatic or renal
function, current or medical history of cancer, recurrent
severe hypoglycemia, proliferative retinopathy or macu-
lopathy, or use of non-herbal Chinese medicine with
unknown content.
2.3 Randomization and Blinding
Eligible participants were randomized in a 2:1 ratio to
insulin degludec (IDeg, 100 U/mL, 3 mL FlexTouch;
Novo Nordisk, Bagsværd, Denmark) or insulin glargine
(IGlar, Lantus, 100 U/mL, 3 mL SoloSTAR; Sanofi-
Aventis, Paris, France) once daily for 26 weeks. Ran-
domization was performed using an interactive voice/web
response system at each dispensing visit. Randomization
was stratified according to region: China/non-China. The
trial was open label, but treatment group assignment was
blinded for internal titration surveillance committee
members, internal safety committee members, external
members of the cardiovascular event adjudication
committee, and everyone involved in defining analysis sets
and performing data review until the database was locked.
2.4 Procedures
At randomization, all subjects discontinued their OADs
except for metformin, which was to be continued main-
taining the pre-randomization dose level and dosing fre-
quency throughout the trial. IDeg was administered once
daily between the start of the main evening meal and
bedtime, and IGlar was administered once daily according
to local labeling. The starting dose of both insulin products
was 10 U with dose titration each week. Mean value of pre-
breakfast self-measured plasma glucose (SMPG) measured
on 3 consecutive days before each scheduled visit or tele-
phone contact was used for optimal titration according to a
titration algorithm, with a target pre-breakfast SMPG of
4.0–4.9 mmol/L (Online Resource Table S1).
Blood samples for central laboratory-analyzed FPG and
HbA1c, andmeasurements for nine-point SMPG profiles were
collected before randomization and after 12, 16, and
26 weeks. Adverse events (AEs) and hypoglycemic episodes
were collected throughout the trial. All other safety parame-
terswere collected at the beginning and end of the trial, and for
body weight and insulin antibodies also after 12 weeks.
Patient-reported outcome questionnaires were completed at
baseline and after 12 and 26 weeks. After 26 weeks, all sub-
jects switched to Neutral Protamine Hagedorn insulin (NPH
insulin, Insulatard/Protaphane/Novolin NTM, 100 IU/mL,
3 mL FlexPen) and continued usingmetformin for a 1-week
follow-up period to allow for the measurement of insulin
antibodies. A 1-week interval (corresponding to[5 9 T)
was necessary to allow forwashout of trial insulin.During this
period, subjects were treated with NPH insulin, which owing
to themuch shorter half-life ensured lower insulin levels at the
antibody sampling time point, consequently reducing the risk
for interference with the antibody measurements.
2.5 Efficacy Assessments
The primary endpoint was the change from baseline in
HbA1c (%) after 26 weeks of treatment. Secondary end-
points included responders in HbA1c (subjects achieving
HbA1c \7 and B6.5 %), responders in HbA1c without
confirmed hypoglycemic episodes during the last 12 weeks
of treatment, change in central laboratory-measured FPG,
nine-point SMPG profiles, within-subject variability
(CV%) in pre-breakfast SMPG, and health-related quality
of life (assessed by Short-Form 36 version 2.0 [SF-36]
questionnaire [18]) and TRIM-D Device [14]. SMPG was
measured using a blood glucose meter (Precision Xtra/
FreeStyle Optimum; Abbott Diabetes Care Inc., Alameda,
CA, USA) with test strips calibrated to plasma values.
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2.6 Safety Assessments
Safety assessments included AEs, hypoglycemic episodes,
injection-site reactions, insulin dose, body weight, and
abnormal findings in physical examination, vital signs,
fundoscopy, electrocardiogram, and laboratory assessments
(hematology, biochemistry, lipids, urinalysis, and insulin
antibodies). Laboratory analyses were performed by stan-
dard methods at Quintiles Central Laboratories (Beijing,
China; West Lothian, UK; Marietta, GA; Centurion, South
Africa), and Diagno´sticos da Ame´rica (Sa˜o Paulo, Brazil).
Insulin antibodies were measured using a subtraction
radioimmunoassay method [19, 20] (Celerion, Fehraltorf,
Switzerland). Confirmed hypoglycemic episodes were
defined as either episodes with SMPG\3.1 mmol/L [21]
(with or without symptoms) or severe episodes requiring
assistance. Episodes occurring between 00:01 and 05:59
(both inclusive) were classified as nocturnal hypoglycemic
episodes. Treatment-emergent AEs, including hypo-
glycemic episodes, were defined as those with onset date
on or after the first day of exposure and until 7 days after
the last day of treatment with IDeg or IGlar.
2.7 Statistical Analyses
The primary objective of the trial was to confirm the effi-
cacy of IDeg plus metformin in controlling glycemia by
comparing the difference in change from baseline in HbA1c
(%) after 26 weeks between IDeg plus metformin and IGlar
plus metformin to a non-inferiority limit of 0.4 %.
The sample size was based on having sufficient repre-
sentation in China. The calculation of statistical power was
performed for the primary objective with the assumption of a
one-sided t test with a significance level of 2.5 %, a mean
treatment difference of zero, and a standard deviation of
1.3 % for HbA1c. A total of 795 subjects had to be ran-
domized to achieve a nominal power of 95 % in the evalu-
ation of the per-protocol (PP) analysis under the assumption
that 15 % of subjects would be excluded from the PP set.
All statistical analyses were performed on the full
analysis set (comprising all randomized subjects) following
the intention-to-treat principle. Efficacy and safety end-
points were summarized using the full analysis set and the
safety analysis set (comprising all subjects exposed to
treatment), respectively. For confirmatory endpoints, the
overall type I error rate was controlled by means of a
hierarchical testing procedure with a priori ordering of
hypotheses [10]. Missing values were imputed using the
last observation carried forward method [22].
The primary endpoint, treatment difference in change
from baseline in HbA1c, was analyzed using an analysis of
variance with treatment, antidiabetic therapy at screening,
sex, and region (China/non-China) as fixed factors, and age
and baseline HbA1c as covariates. Sensitivity analyses of
the primary analysis were performed on the PP set, using
the same model as above, on the full analysis set using a
simple model including only treatment as a fixed factor and
HbA1c baseline value as a covariate, and with a linear
mixed model for repeated measures using an unstructured
residual covariance matrix to evaluate the sensitivity of last
observation carried forward for dealing with missing data.
Responders in HbA1c (for targets of\7 and B6.5 %),
and responders achieving these targets without confirmed
hypoglycemic episodes in the previous 12 weeks of treat-
ment, were analyzed with a logistic regression model with
logit link using treatment, antidiabetic therapy at screening,
sex and region as fixed factors, and age and baseline HbA1c
as covariates. The number of treatment-emergent hypo-
glycemic episodes was analyzed with a negative binomial
regression model including treatment, antidiabetic therapy
at screening, sex and region as fixed factors, age as a
covariate, and log exposure as an offset.
Treatment differences in FPG, pre-breakfast SMPG,
mean and fluctuation in 9-point SMPG, prandial plasma
glucose (PG) increments, nocturnal PG differences, body
weight, SF-36 and TRIM-D Device scores were analyzed
similarly to the primary endpoint, using the relevant
baseline value as covariate (if available). Within-subject
variability (CV%) of pre-breakfast SMPG was estimated
from a linear mixed model with treatment, antidiabetic
therapy at screening, sex and region as fixed factors, age as
a covariate, and subject as a random factor. All other
endpoints were summarized descriptively. All statistical
analyses were performed using SAS version 9.3 (SAS
Institute, Cary, NC, USA).
3 Results
3.1 Subject Disposition and Baseline Characteristics
Of the 1168 subjects screened for eligibility, 335 subjects
failed to meet the screening criteria and 833 subjects were
randomized. In accordance with the 2:1 randomization
ratio (IDeg:IGlar), 555 subjects were randomized to IDeg
and 278 to IGlar. Two subjects in the IDeg group withdrew
consent prior to receiving treatment. A total of 94.2 and
91.4 % of the randomized subjects completed the trial with
IDeg and IGlar, respectively, the main reason for discon-
tinuation being withdrawal of consent (Fig. 1).
The treatment groups were well matched at baseline
with a duration of diabetes of approximately 8 years, and a
mean HbA1c of 8.3 % (Table 1). The mean age was
56 years and women comprised approximately half of the
subjects. Most subjects (67 %) were Asian non-Indian.
Two thirds of subjects were from China (67 %), while the
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remaining subjects were evenly distributed between the
other five countries (5–9 % of the subjects in each coun-
try). Subjects were insulin naı¨ve at baseline, and approxi-
mately two thirds of subjects were treated with OAD
combination therapy.
3.2 Glycemic Control
Mean HbA1c over time was similar between the treatment
groups (Fig. 2a). During the 26-week treatment period,
mean (standard deviation [SD]) HbA1c decreased from 8.3
(0.8) % to 7.0 (0.9) % in both treatment groups, consistent
with the treat-to-target design. The groups showed similar
mean (SD) changes from baseline in HbA1c; -1.3 (1.1) %
points for IDeg and -1.2 (1.0) % points for IGlar. The
estimated treatment difference (ETD) IDeg-IGlar [95 %
CI] was -0.05 % points [-0.18 to 0.08] confirming the
non-inferiority of IDeg to IGlar in HbA1c reduction. The
result of the primary analysis was supported by similar
results in the PP analysis and additional sensitivity analyses
(Online Resource Table S2).
The proportion of subjects who achieved the HbA1c
target of\7.0 % at the end of the trial was comparable;
54.2 % with IDeg and 51.4 % with IGlar (estimated odds
ratio, EOR [95 % CI] IDeg/IGlar: 1.14 [0.84 to 1.54]).
Similarly, the proportion of subjects who achieved the
more strict target of B6.5 was 35.7 and 31.3 % with IDeg
and IGlar, respectively (EOR [95 % CI]: 1.23 [0.89 to
1.70]). The proportion of subjects achieving HbA1c\7.0 %
without confirmed hypoglycemia in the previous 12 weeks
of treatment was 46.8 % with IDeg and 42.4 % with IGlar.
The odds of achieving this target was numerically higher in
the IDeg group with EOR [95 % CI] of 1.24 [0.91 to 1.69],
although not statistically significant. Similarly, the pro-
portion of subjects achieving the target of B6.5 % in
HbA1c without confirmed hypoglycemia was 31.8 and
26.4 % in the IDeg and IGlar groups, respectively (EOR
[95 % CI]: 1.33 [0.94 to 1.87]).
The decrease in FPG over time was similar between
treatments with the most pronounced decrease during the
first 12 weeks and almost unchanged in the remaining part
of the treatment period (Fig. 2b). The mean (SD) FPG at
baseline was 9.4 (2.4) mmol/L in the IDeg group and 9.4
(2.5) mmol/L in the IGlar group. After 26 weeks of treat-
ment, FPG had decreased by 3.35 (2.91) mmol/L with IDeg
and 3.14 (2.71) mmol/L with IGlar to mean (SD) levels of
6.0 (2.0) mmol/L and 6.3 (1.9) mmol/L, respectively. The
ETD [95 % CI] for IDeg-IGlar in change from baseline in
FPG was -0.26 mmol/L [-0.53 to 0.02] and did not reach
statistical significance.
1168 subjects screened 
833 subjects randomized 
335 screening failures 
• 307 did not comply with all inclusion/exclusion criteria 
• 18 withdrew informed consent 
• 10 other reasons 
555 randomized to IDeg (100.0%) 278 randomized to IGlar (100.0%) 
553 received treatment (99.6%) 278 received treatment (100.0%) 
2 subjects did not receive treatment 
due to withdrawal of consent (0.4%) 
523 completed treatment (94.2%) 
32 withdrawn (5.8%) 
• 15 withdrew informed consent 
• 3 due to adverse events 
• 3 due to non-compliance 
• 1 met withdrawal criteria 
• 4 lost to follow up 
• 6 due to other reasons 
24 withdrawn (8.6%) 
• 12 withdrew informed consent 
• 3 due to adverse events 
• 3 due to non-compliance 
• 2 lost to follow up 
• 4 due to other reasons 
254 completed treatment (91.4%) 
555 in full analysis set (100.0%) 
538 in per protocol set (96.9%) 
553 in safety analysis set (99.6%) 
278 in full analysis set (100.0%) 
266 in per protocol set (95.7%) 
278 in safety analysis set (100.0%) 
Fig. 1 Trial flow diagram. The full analysis set included all
randomized subjects. The safety analysis set included all randomized
subjects who received at least one dose of trial product. Most subjects
withdrawn for ‘‘other’’ reasons were randomized in error (5 in the
IDeg group, 3 in the IGlar group). % proportion of randomized
subjects
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The nine-point SMPG profiles appeared similar
between the two treatment groups at baseline and at the
end of trial and similar reductions in PG levels were
observed for both treatment groups (Fig. 2c). The within-
subject variability in pre-breakfast SMPG as measured by
CV% was 14.2 % with IDeg and 12.9 % with IGlar (es-
timated treatment ratio [95 % CI] IDeg/IGlar of 1.10
[1.02 to 1.18]).
3.3 Insulin Doses
In both treatment groups, the mean daily basal insulin dose
was 10 U (0.14 U/kg) at baseline, corresponding to the pre-
defined starting dose, and increased throughout the trial,
most rapidly during the initial weeks (Online Resource
Fig. S1). At the end of trial, mean daily basal insulin doses
were similar in the treatment groups; 0.49 U/kg (40 U) for
IDeg and 0.50 U/kg (39 U) for IGlar.
3.4 Patient-Reported Outcome Measurements
The total score (device bother and device function) for
TRIM-D Device at the end of treatment was 74.3 in the
IDeg group and 71.6 in the IGlar group, with a statistically
significant difference between treatments in favor of IDeg
(ETD [95 % CI] IDeg-IGlar: 2.2 [0.2 to 4.3]).
Table 1 Demography and
baseline characteristics (full
analysis set)
IDeg OD (n = 555) IGlar OD (n = 278)
Female, n (%) 256 (46.1) 146 (52.5)
Race
White 133 (24.0) 70 (25.2)
Black or African American 12 (2.2) 9 (3.2)
Asian Indian 8 (1.4) 1 (0.4)
Asian non-Indian 375 (67.6) 187 (67.3)
American Indian or Alaska Native 1 (0.2) 0 (0.0)
Other 26 (4.7) 11 (4.0)
Ethnicity
Hispanic or Latino 47 (8.5) 23 (8.3)
Age, years 55.9 (9.7) 56.6 (9.2)
Body weight, kg 75.5 (15.6) 73.8 (16.1)
BMI, kg/m2 27.4 (4.7) 27.0 (4.6)
Duration of diabetes mellitus, years 7.55 (5.28) 8.26 (5.45)
HbA1c, % 8.3 (0.9) 8.3 (0.8)
FPG, mmol/L 9.4 (2.4) 9.4 (2.5)
Antidiabetic regimen at screening, n (%)
Metformin monotherapy 189 (34.1) 87 (31.3)
Metformin ? 1 OAD 314 (56.6) 159 (57.2)
Metformin ?[1 OAD 52 (9.4) 31 (11.2)
Metformin ? 1 OAD ? insulin therapy 0 (0.0) 1 (0.4)
OADs at screening, n (%)
Metformin 555 (100.0) 278 (100.0)
Sulfonylurea 290 (52.3) 159 (57.2)
a-Glucosidase inhibitor 66 (11.9) 38 (13.7)
Glinide 34 (6.1) 15 (5.4)
DPP-IV inhibitor 29 (5.2) 10 (3.6)
Complications at screening, n (%)
Diabetic complicationsa 133 (24.0) 67 (24.1)
Vascular disorders 314 (56.6) 147 (52.9)
Data are mean (standard deviation) based on the full analysis set unless otherwise stated
IDeg insulin degludec, IGlar insulin glargine, OD once daily, % proportion of subjects, BMI body mass
index, HbA1c glycosylated hemoglobin, FPG fasting plasma glucose, OAD oral antidiabetic therapy, DPP-
IV dipeptidyl peptidase IV
a Diabetic complications included: diabetic retinopathy, retinopathy hemorrhage, diabetic neuropathy,
diabetic nephropathy, microalbuminuria, diabetic vascular disorder, diabetic microangiopathy, diabetic
macroangiopathy, diabetic ketoacidosis
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The physical and mental scores of the SF-36 ques-
tionnaire improved marginally in both groups during
the trial. No statistically significant differences were
shown between IDeg and IGlar in any of the SF-36
domains.
3.5 Hypoglycemic Episodes
The rate of confirmed hypoglycemia was 85 and 97 epi-
sodes per 100 patient-years of exposure with IDeg and
IGlar, respectively. IDeg was associated with a 20 % lower
rate of confirmed hypoglycemia, although not statistically
significant (estimated rate ratio, [95 % CI] IDeg/IGlar:
0.80 [0.59 to 1.10]) (Table 2). The rate of nocturnal con-
firmed hypoglycemia was 22 and 24 episodes per 100
patient-years of exposure in the IDeg and IGlar groups,
respectively, with an estimated rate ratio [95 % CI] for
IDeg/IGlar of 0.77 [0.43 to 1.37] (Table 2).
Across the entire 26-week trial period, IDeg had a
constant rate of overall and nocturnal confirmed hypo-
glycemic episodes, while IGlar had a low rate in the initial
part of the trial and an increasing rate as the trial pro-
gressed (Fig. 3a, b).
Two severe hypoglycemic episodes were reported by
two subjects in each group (0.4 and 0.7 % of subjects for
IDeg and IGlar, respectively) (Table 2). Owing to the low
number of severe episodes no statistical analysis was
performed.
3.6 Adverse Events
In total, 53 % of subjects treated with IDeg and 58 % of
subjects treated with IGlar reported at least one treatment-
emergent AE during the trial (Online Resource Table S3).
Most of the events (97 %) were of mild or moderate
severity. A total of 11.9 % of subjects treated with IDeg
and 10.8 % of subjects treated with IGlar reported AEs
assessed as probably or possibly related to trial product.
The most frequently reported AEs in each treatment group
were upper respiratory tract infection and nasopharyngitis,
both of which were reported in C5 % of subjects. The
proportion of subjects with injection-site reactions was low
and similar between treatment groups (1.6 % in the IDeg
group and 0.7 % in the IGlar group). In total, six subjects
withdrew because of AEs, three (0.5 %) in the IDeg group
and three (1.1 %) in the IGlar group, and no specific pat-
tern of AEs leading to withdrawal was noted.
Serious AEs (SAEs) were reported by 2.9 % of subjects
(16/553) in the IDeg group and 3.6 % of subjects (10/278)
in the IGlar group. No SAEs were reported with a fre-
quency C1 % in either treatment group. Of the SAEs, 4 of
18 events were considered possibly or probably related to
IDeg and 3 of 12 events were considered possibly or
probably related to IGlar. The SAEs considered related to
IDeg were hypoglycemia, cerebral infarction, cerebrovas-
cular accident, and hypoglycemic unconsciousness (one
Fig. 2 Glycemic control (full analysis set). a Mean HbA1c across the
26-week treatment period, b mean FPG across the 26-week treatment
period, c 9-point SMPG profiles at baseline (week 0) and end of
treatment (week 26). Glucose measurements for 9-point profiles were
performed just before ameal and 90 minutes after start of themeal. Data
are mean ± SEM.Missing data after baseline are imputed with the last
observation carried forward method. IDeg insulin degludec, IGlar
insulin glargine, HbA1c glycosylated hemoglobin, FPG fasting plasma
glucose, SMPG self-measured plasma glucose, ?90 min 90 min after
start of the preceding meal, SEM standard error of the mean
Comparison of insulin degludec and insulin glargine in T2D 245
episode each), and SAEs considered related to IGlar were
two episodes of hypoglycemia and one episode of
palpitations.
Three serious and one non-serious malignant neoplasms
were reported during the trial. In the IDeg group, non-
small-cell metastatic lung cancer and basal cell carcinoma
(non-serious) were reported, and in the IGlar group, rectal
cancer and gastric cancer were reported. All malignant
neoplasms were considered unrelated to the trial product.
One death occurred during the trial in the IGlar group.
The cause of death was reported as cardiac failure, peri-
tonitis, and gastric cancer with perforation, and was con-
sidered unrelated to treatment.
A total of six major adverse cardiovascular events were
reported, distributed similarly between groups; four strokes
in the IDeg group (0.7 % of subjects) and two strokes in the
IGlar group (0.7 % of subjects).
3.7 Other Safety Results
Body weight increased similarly throughout the trial in
both treatment groups with mean (SD) weight gain in the
IDeg and IGlar groups of 2.2 (3.1) and 1.8 (3.1) kg,
respectively (ETD [95 % CI] IDeg-IGlar: 0.34 kg [-0.09
to 0.78]). There were no clinically relevant differences
between treatments in laboratory analyses (hematology,
biochemistry, lipids, and urinalysis), physical examination
findings, electrocardiogram, vital signs, or fun-
doscopy/fundus photography during the trial. The mean
level of insulin antibodies specific for IDeg and IGlar was
zero at baseline and did not change during the trial. Only
single cases of IDeg/IGlar-specific antibodies were detec-
ted during the treatment period. Mean values (SD) of
insulin antibodies cross-reacting between IDeg/IGlar and
human insulin increased from 2.0 (8.7) % bound/total with
IDeg and 1.6 (7.5) % bound/total with IGlar at baseline to
3.2 (11.1) % bound/total for IDeg and 4.9 (12.5) %
bound/total for IGlar at the end of the wash-out. Only a
minor fraction of subjects in the IDeg and IGlar treatment
groups developed cross-reacting antibodies. No correlation
between cross-reacting or insulin-specific antibodies and
HbA1c or insulin dose was observed.
4 Discussion
In this trial, treatment with IDeg in a T2DM population
with 67 % Chinese subjects, initiating insulin treatment
confirmed its efficacy and safety when compared with
IGlar. In accordance with previous trials in the large clin-
ical development program for IDeg, non-inferiority vs.
IGlar in terms of glycemic control was met [8–10]. Despite
the large sub-population of Chinese subjects with an
assumed high carbohydrate intake [23], basal-only treat-
ment ensured adequate glycemic control in a large pro-
portion of subjects (HbA1c\7.0 %; 54 % with IDeg and
51 % with IGlar) without requiring additional bolus
insulin.
As shown by the total TRIM-D Device score, subjects
were more satisfied with the IDeg device compared with the
IGlar device. The result in this trial is consistent with a
previous crossover trial where subjects were randomized to
receive either IDeg or IGlar for 16 weeks, and were crossed
over to the alternative basal insulin for the remaining
16 weeks [15]. In that trial, an even larger treatment dif-
ference in TRIM-D Device score in favor of IDeg was seen.
Importantly, subjects in that trial were using insulin vials
and syringes prior to the trial; thus, the results were not
affected by recent insulin pen experience, similarly to the
trial reported here where the subjects were insulin naı¨ve.
Table 2 Frequency and analysis of hypoglycemic episodes (safety and full analysis sets)
IDeg OD (n = 553) IGlar OD (n = 278) Estimated rate ratio
IDeg/IGlar [95 % CI]
Subjects n (%) Episodes Ratea Subjects n (%) Episodes Ratea
Overall severeb 2 (0.4) 2 1 2 (0.7) 2 1 ND
Overall confirmedc 128 (23.1) 228 85 79 (28.4) 130 97 0.80 [0.59 to 1.10]
Nocturnal confirmedc,d 40 (7.2) 58 22 25 (9.0) 32 24 0.77 [0.43 to 1.37]
Summary statistics for the safety analysis set and statistical analysis on the full analysis set
The estimated rate ratio was analyzed in a negative binomial regression model including treatment, antidiabetic therapy at screening, sex and
region as fixed factors, age as covariate, and log exposure as offset. Statistical analysis of severe hypoglycemic episodes was not performed
because of too few episodes
IDeg insulin degludec, IGlar insulin glargine, OD once daily, CI confidence interval, ND not done
a Number of hypoglycemic episodes per 100 patient-years of exposure
b Requiring assistance of another person to actively administer carbohydrate, glucagons, or other resuscitative actions
c Includes episodes of severe hypoglycemia as well as hypoglycemic episodes with confirmed plasma glucose\3.1 mmol/L
d Time of onset between 00:01 and 05:59 (both inclusive)
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The treat-to-target design allows for direct comparison of
safety measurements such as hypoglycemia without con-
founding differences in HbA1c. In this trial, 20 and 23 %
lower rates of overall and nocturnal confirmed hypo-
glycemia, respectively, were found with IDeg compared to
IGlar, although the differences did not reach statistical sig-
nificance (Table 2). This was accompanied by the odds of
achieving the glycemic targets of HbA1c \7 and B6.5 %
without confirmed hypoglycemia being 24 and 33 % higher
with IDeg than with IGlar, although not statistically signif-
icantly different. Similar results have been seen in other
IDeg trials of 26 weeks duration [8, 9], and a statistically
significant difference in nocturnal confirmed hypoglycemia
rates was shown in a 52-week trial (36 % lower rate for
IDeg compared with IGlar) [10]. A pre-specified meta-
analysis has been conducted to confirm superiority of IDeg
over IGlar for hypoglycemic episodes using pooled indi-
vidual subject-level data from seven previous IDeg trials.
For basal-only insulin treatment in insulin-naı¨ve subjects
with T2DM, the meta-analysis showed rates of overall and
nocturnal confirmed hypoglycemic episodes that were sta-
tistically significantly lower by 17 and 36 %, respectively,
for IDeg compared with IGlar [13]. Recently, a meta-anal-
ysis performed on the same data, using three alternative
definitions of nocturnal hypoglycemia, supported statisti-
cally significantly lower rates of nocturnal hypoglycemia in
the range of 27–44 % with IDeg vs. IGlar in insulin-naı¨ve
subjects with T2DM [24]. Thus, the numerical differences in
hypoglycemia rate between IDeg and IGlar observed in the
present trial are in accordance with comprehensive pooled
analyses of previous trials in insulin-naı¨ve subjects with
T2DM on basal-only therapy.
In this trial, the within-subject day-to-day variation in
pre-breakfast SMPG, assessed by CV% was 12.9 % with
IGlar and 14.2 % with IDeg, with the difference between
treatments being statistically significant. In other trials
testing IDeg vs. IGlar in T2DM with basal-only insulin
treatment, generally higher levels of within-subject vari-
ability in pre-breakfast SMPG were seen (CV% of
16–18 %) with statistically significantly lower CV% in
favor of IDeg [9], or no difference between treatments [8,
10]. Thus, the observed difference in the present trial is not
believed to be of any clinical relevance.
The trial had several strengths. Including an insulin-
naı¨ve population ensured that expectation bias was
reduced. Furthermore, the treat-to-target design used to
achieve improved and similar glycemic control in the two
treatment groups ensured that comparisons among groups
in frequency and severity of hypoglycemia were inter-
pretable in ultimate risk-benefit assessments [22]. The trial
was limited by the open-label design, but because appro-
priate placebo injection devices were not available, it was
not possible to employ a fully blinded double-dummy
design. Still, because accurate quantification of hypo-
glycemic episodes was important, we tried to limit
reporting bias by using an objective definition of hypo-
glycemia, i.e., either PG \3.1 mmol/L [21] (where the
majority of subjects will have symptoms) or severe hypo-
glycemia requiring assistance. As in any open-label trial,
there was a risk of greater caution when titrating the dose
of the new drug (IDeg); however, when comparing IDeg
with IGlar this was not reflected in the change in HbA1c
and FPG over time, or in the proportion of subjects
reaching HbA1c targets at the end of the trial. Because the
dosing time of IGlar was not captured in this trial, it was
not possible to explore the impact of dosing time on gly-
cemic control. Finally, as in any other clinical trial, the
population was selected based on predefined inclusion and
Fig. 3 Cumulative number of confirmed hypoglycemic episodes
across the 26-week treatment period (safety analysis set). a Overall
confirmed hypoglycemic episodes. b Nocturnal confirmed hypo-
glycemic episodes. Confirmed hypoglycemic episodes included
episodes of severe hypoglycemia as well as hypoglycemic episodes
with confirmed plasma glucose \3.1 mmol/L. Nocturnal hypo-
glycemic episodes were defined as episodes with time of onset
between 00:01 and 05:59 (both inclusive). IDeg insulin degludec,
IGlar insulin glargine
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exclusion criteria, implying that the clinical applicability of
this trial is limited to patients who fit those criteria.
5 Conclusion
This trial confirmed the non-inferiority of IDeg vs. IGlar in
HbA1c reduction when initiating once-daily basal insulin in
patients with T2DM. IDeg provided adequate glycemic con-
trol with a low rate of overall and nocturnal confirmed
hypoglycemia, and no safety issues were detected. Overall,
the findings from this trial, with two thirds of subjects enrolled
in China, demonstrate that IDeg provides a new and safe
option for initiating insulin therapy in insulin-naı¨ve patients
with T2DM who are inadequately controlled on OADs.
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